advanced search
Audrey Furness
Marketing Executive
ONdrugDelivery

Is this your profile?

About

Audrey Furness is Marketing Executive for ONdrugDelivery Magazine.

Contributions

Inhaled and nasal Covid-19 vaccine progress
Specialist respiratory drug product news publication OINDP News, has reported progress from several intranasal and inhaled COVID-19 vaccine development programmes, including from Altimmune, APEPTICO, a partnership between Neurimmune and Ethris, and a partnership between UW–Madison, FluGen and Bharat Biotech.

More contributions

#97_May_2019_Roquette_featured
Combating Coronavirus: Cyclodextrins in Treatment & Prevention
Roquette has identified its KLEPTOSE® hydroxypropyl beta-cyclodextrins (HPβCD) as potentially effective to help the joint efforts of the scientific and pharmaceutical communities working on treating and preventing new emerging viruses such as the coronavirus. HPβCD can effectively act as a safe, enabling excipient for solubility enhancement of antiviral drugs, stability improvement of therapeutic monoclonal antibodies, and as a vaccine adjuvant. 
MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission
With evidence indicating that the established antiparasitic ivermectin can kill coronavirus in a laboratory setting in under 48 hours, MedinCell has published data showing that long-acting formulations of ivermectin can be designed with varying doses and durations with its BEPO® technology and is investigating whether a long-acting product could be effective in breaking the chain of viral transmission.
INHALER FOR DIRECT PULMONARY DELIVERY OF ANTI-IL-6 MAB IN COVID-19
Tiziana Life Sciences has developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the lung in COVID-19. The company believes TZLS-501 (anti-IL6R) combined with this newly introduced inhalation technology may rapidly inhibit inflammation in lungs and in combination with intravenous administration may deplete circulating levels of IL-6 and potentially halt progression of COVID-19-mediated lung damage and death.
DEVICE DESIGN CONSULTANCIES JOIN FORCES, STEP-UP TO THE COVID-19 VENTILATOR CHALLENGE
Leading device design consultancies Cambridge Consultants, PA Consulting, Sagentia, Team Consulting and TTP , with industrial assistance from MetLase, have joined forces to answer the UK  government's call for the rapid development and manufacture of vital ventilators for patients suffering with severe symptoms of COVID-19.
Development of IMV’s DPX-COVID-19 Vaccine Progresses Apace
Canadian biotech company IMV has made impressively rapid, solid progress on the development of a vaccine candidate against the novel coronavirus, using its lipid-based vaccine delivery platform, DPX. New developments in just two weeks include, include: initiation of peptide candidate manufacturing, cGMP scale-up plans, preclinical models/assays; and Phase I clinical trial design completed, with discussions with Health Canada already underway also.
Aquavit Developing Microchannel Drug Delivery Device / Novel Compositions for Vaccine Against COVID-19
Aquavit Pharmaceuticals is applying its AQUAGOLD® microchannel drug delivery device in the development of a self-administered dermal vaccine against COVID-19 caused by the SARS-CoV-2 coronavirus.
How the current pandemic will shape healthcare innovation for the next decade
In its COVID-19 announcement, Ximedica has confirmed that its manufacturing facility remains open under the “essential service” classification and that is focusing on US national efforts to help address the challenges surrounding ventilator and PPE supplies. It also highlighted its core strength in engineering, with more than 200 engineers who have established several highly effective means of remote collaboration. 
EUROFINS CDMO Launches “Direct To Patient” Service for Continuity of Treatment for Customers’ Clinical Trial Patients
CDMO Eurofins  has launched a Direct to Patient service to assure the continued supply of treatments to its customers' clinical trial patients.
Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months
UK biopharma company Stabilitech is developing OraPro-COVID-19,  applying its OraPro technology with the aim of developing a viral vector with six weeks, and having a capsule ready for animal testing within 12 weeks.
TEQ supporting ‘Essential Business’ activity with European sourcing of medical packaging
TEQ is delivering a range of medical packaging solutions for customers working to address critical health needs related to covid-19.
Vero Biotech gets okay for expanded access to its Genosyl DS iNO system to treat COVID-19 patients
The US FDA has granted “Expanded Access Emergency Use” to Vero Biotech immediately to use its proprietary inhaled nitric oxide (iNO) delivery system, GENOSYL DS, in the treatment of cardiopulmonary symptoms associated with COVID-19. The agency recently approved GENOSYL (NO) gas, for inhalation for the treatment of persistent pulmonary hypertension of the newborn.
N4 demonstrating utility of Nuvec® vaccine delivery system in COVID-19 vaccines using COVID-19 DNA plasmid
N4 Pharma has initiated a proof of concept project using a Covid-19 DNA plasmid to demonstrate the utility of its Nuvec® silica nanoparticle  vaccine delivery system for potential collaboration partners developing Covid-19 DNA or RNA vaccines.
COVID-19, what’s left to be said and done?…well, everything!
John Cahill, Director, Senior Consultant, Quality & Compliance, PharmaLex Ireland, provides an update on the status of several COVID-19 vaccine and therapeutic development programmes, emphasising the considerable efforts being made by industry, regulatory agencies and others, to accelerate development in what is normally, due to the need for stringent regulation, a notoriously slow-moving sector. 
Ampio to Study Nebulised Ampion Anti-Inflammatory Biologic in COVID-19 Patients
Ampio Pharmaceuticals is preparing an expanded access US FDA protocol to study potential benefit of nebulised treatment with Ampion in COVID-19-induced acute respiratory distress syndrome (ARDS), an immediately life-threatening condition. 
Windtree Therapeutics to study its KL4 surfactant for COVID-19 pulmonary effects
Windtree Therapeutics plans a pilot study to assess its KL4 surfactant's ability to impact key respiratory parameters in ventilated COVID-19 patients. The COVID-19 virus infects the specific cells that make pulmonary surfactant and is believed to result in inadequate levels of functional surfactant.
eTheRNA launches international consortium, starts development of cross-strain protective CoV-2 mRNA vaccine
An international consortium is pooling resources to develop a nasally delivered, cross-strain protective CoV-2 mRNA vaccine. Clinical testing is scheduled for early 2021. Organisations involves include eTheRNA, EpiVax, REPROCELL, Nexelis, and CEV
Gerresheimer part of critical infrastructure, products include vital drug delivery devices
In its COVID-19 announcement, Gerresheimer has stated that it is part of the critical infrastructure of the countries in which it operates, producing vital packaging for medicines, drug delivery devices and packaging for food, beverages and hygiene and personal care products.
Catalent Responds to the Global Outbreak of COVID-19
Catalent has noted that many governments of the countries where it operates have recognised its work as essential meaning all Catalent operating facilities remain open. The company also said it was working with several customers on COVID-related antivirals, vaccines, and treatments for symptoms and effects of the disease.
With precision metal components being used in inhalers & similar devices, Advanex acknowledges critical role in supply chain
Advanex acknowledges critical role in supply chains with precision metal components being used in inhalers & similar devices, and commits to maintaining supply during turbulent period.
Elcam Medical facilities Recognised by local authorities as essential, enabling continuation of production
All Elcam facilities have been recognised by the local authorities as an essential facility to enable the continuity of production. (See statement by the Israeli Ministry of Economy and Industry). Currently the company does not foresee any disruption to our operation.
Digital RDD 2020 starts April 26, replaces cancelled RDD California
For 2020, RDD is going digital. The organisers, focused on quality, have committed to providing delegates a digital conference venue open 24/7 with the following features: Digital Auditorium; Digital Platinum Sponsor Sessions; Digital Scientific Poster Session; Posters on the Digital Podium; Digital Exhibition; Digital Networking; Digital Library; Digital Personal Proceedings.
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Lexaria is to investigate how its patented DehydraTECH drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19.  Lexaria intends to expand collaboration with leading laboratories as soon as possible.
ACG releases letter to customers in response to COVID-19
ACG has released a letter to its customers in response to the COVID-19 outbreak, and reaffirmed its commitment to providing uninterrupted supply of its products and services, and factories in all locations around the world are working at full capacity. ACG has also ensured the supply of its own raw materials for many months.
Top